Rapid Micro Biosystems
Innovative products for fast, accurate, and efficient detection of microbial contamination in the manufacture of pharmaceuticals, biologics and biotechnology products.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | N/A | IPO | |
| Total Funding | 000k | ||
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (3 %) | 45 % | (26 %) | 31 % | 25 % | 16 % | 21 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (180 %) | (200 %) | (369 %) | (237 %) | (166 %) | (129 %) | (96 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (231 %) | (316 %) | (355 %) | (233 %) | (167 %) | (132 %) | (99 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 41 % | 42 % | 75 % | 57 % | 52 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Rapid Micro Biosystems, Inc. is an innovative life sciences technology company specializing in automation solutions that streamline the manufacturing and expedite the release of healthcare products. The company serves large and complex pharmaceutical manufacturing operations, focusing on biologics, vaccines, cell and gene therapies, and sterile injectables. Rapid Micro Biosystems operates in the life sciences and healthcare market, providing mission-critical automation solutions that modernize microbial quality control (MQC) testing workflows. The company's flagship Growth platform automates these traditionally manual processes, enhancing efficiency and safety in product release. The business model revolves around selling and supporting its automation platforms, generating revenue through product sales, maintenance contracts, and service agreements.
Keywords: automation, life sciences, healthcare, microbial quality control, pharmaceutical, biologics, vaccines, cell therapy, gene therapy, sterile injectables.